Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Futura Medical (FUM) Share Price & Analysis

FUM Stock Chart & Stats

GBX 0.18GBX 0.00(0.00%)
At close: 3:59 PM GMT
0.2 p0.3 p0.4 p10 Aug24 Aug7 Sep21 Sep5 Oct19 Oct2 Nov
Day’s Range
GBX 0.17 - GBX 0.22
52-Week Range
GBX 0.16 - GBX 2.80
Previous Close
GBX 0.18
Volume
N/A
Average Volume (3M)
14.52M
Market Cap
GBP 2.59M
Enterprise Value
GBP 1.78M
Total Cash (Recent Filing)
GBP 1.24M
Total Debt (Recent Filing)
GBP 0
Price to Earnings (P/E)
―
Beta
0.83
Next Earnings
Apr 14, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Zero Debt

Zero debt reduces fixed financial obligations and refinancing exposure, giving Futura greater flexibility while it funds regulatory work and partner-led commercial expansion. This conservative leverage profile can help the company withstand volatility without debt service further consuming operating resources.

Strong Gross Margin

Gross margins in the mid-to-high 60% range across 2024–2025 indicate that MED3000 has potentially attractive unit economics before operating expenses. If commercial volume scales through partners, this margin profile could support better operating leverage, although current costs remain high.

Partner-Led Expansion Model

An out-licensing model can extend international reach without requiring Futura to build a large in-house salesforce. Partner manufacturing, distribution and sell-through can create royalties, milestones and profit-share opportunities, allowing expansion to rely on commercial partners’ territory capabilities.

Bears Say

Revenue And Profit Volatility

The roughly 79% revenue decline in 2025 and swing from 2024 profit to a sizable loss show weak earnings durability. Such volatility makes it harder to fund development and commercial activity internally and indicates that partner-led rollout has not yet produced consistent financial performance.

Persistent Cash Burn

Meaningfully negative operating cash flow and persistently negative free cash flow indicate ongoing cash burn rather than self-funded operations. Continued burn can increase reliance on external funding or future commercial receipts, potentially constraining investment in regulatory approvals and market expansion.

Shrinking Capital Base

Material equity decline from 2024 to 2025, alongside a smaller asset base, indicates that losses are eroding the company’s financial resources. Even with zero debt, a shrinking capital base can reduce resilience and limit the capacity to sustain development and commercialisation before cash generation improves.

Futura Medical News

FUM FAQ

What was Futura Medical’s price range in the past 12 months?
Futura Medical lowest share price was 0.16 p and its highest was 2.80 p in the past 12 months.
What is Futura Medical’s market cap?
Futura Medical’s market cap is £2.59M.
When is Futura Medical’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Futura Medical’s earnings last quarter?
Futura Medical released its earnings results on Sep 01, 2026. The company reported -0.002 p earnings per share for the quarter.
Is Futura Medical overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Futura Medical pay dividends?
Futura Medical does not currently pay dividends.
What is Futura Medical’s EPS estimate?
Futura Medical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Futura Medical have?
Futura Medical has 1,482,327,800 shares outstanding.
What happened to Futura Medical’s price movement after its last earnings report?
Futura Medical reported an EPS of -0.002 p in its last earnings report. Following the earnings report the stock price went down -0.263%.
Which hedge fund is a major shareholder of Futura Medical?
Currently, no hedge funds are holding shares in GB:FUM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology